Meeting Banner
Abstract #4732

The feasibility of ADC in optimizing chemotherapy for 5-FU-resistant gastric cancer with mouse model: when should replace 5-FU with paclitaxel?

Jia Sun1, Lai-yun Zhang1, Lei Yang1, Zhu-lin Li1, Qing-lei Shi2, and Tao Jiang1
1Beijing Chaoyang Hospital of Capital Medical Universit, Beijing, China, 2Siemens Healthcare,MR Scientific Marketing,Beijing China, Beijing, China

In this study, we verified the feasibility of apparent diffusion coefficient (ADC) values in predicting chemotherapy response and optimizing chemotherapy regimen for gastric cancer that is resistant 5-FU with mouse model. We found that based on the early changes of ADC to replace 5-FU with paclitaxel in advance can effectively reduce tumor burden which means it may be possible to use ADC values as a reliable bio-marker in predicting chemotherapy response and optimizing chemotherapy regimen for gastric cancer.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here